In biggest-ever bet on using AI to design drugs, biotech heavyweights launch Xaira with $1B+ in backing – Endpoints News
From L-R: Marc Tessier-Lavigne, Bob Nelsen, David Baker and Vik Bajaj
April 23, 2024 07:00 AM EDTUpdated 11:05 AM
Startups
Deals
R&D

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

A star-stud­ded mix of ven­ture cap­i­tal­ists and sci­en­tists, backed by more than a bil­lion dol­lars, is launch­ing an am­bi­tious biotech that aims to rein­vent drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA green­lights Geron’s ime­tel­stat to treat ane­mia in cer­tain can­cer pa­tients

Google's par­ent com­pa­ny Al­pha­bet poach­es Eli Lil­ly CFO; More changes at Ex­sci­en­tia

Ab­b­Vie and Al­pha­bet's Cal­i­co added to Op­er­a­tion Warp Speed for rare dis­eases

Neu­ro­science com­pa­ny Rap­port Ther­a­peu­tics lists on Nas­daq

J&J’s deal­mak­er: Plen­ty of ‘fire­pow­er,’ but most­ly fo­cused on tuck-in M&A

At AS­CO: big read­outs, rev­enue ques­tions, and the ups and downs of AD­Cs

A service from the Financial Times